Press release
Cholangiocarcinoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Key Takeaways from the Cholangiocarcinoma Pipeline Report
* DelveInsight's Cholangiocarcinoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma treatment.
* The leading companies working in the Cholangiocarcinoma Market include Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
* Promising Cholangiocarcinoma Pipeline Therapies in the various stages of development include Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib , and others.
* April 2024:- TransThera Sciences (Nanjing), Inc.- A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors. This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
Request a sample and discover the recent advances in Cholangiocarcinoma Treatment Drugs @ Cholangiocarcinoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Cholangiocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Cholangiocarcinoma Overview
Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree and showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma. Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections.
Find out more about Cholangiocarcinoma Therapeutics Assessment @ Cholangiocarcinoma Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cholangiocarcinoma Emerging Drugs Profile
* Pembrolizumab: Merck Sharp & dohme
* E7090: Eisai
* ABC294640: RedHill Biopharma Limited
* TT-00420: TransThera Science
* KIN-3248: Kinnate Biopharma
Cholangiocarcinoma Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the Cholangiocarcinoma therapies. The Cholangiocarcinoma companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & dohme.
DelveInsight's Cholangiocarcinoma pipeline report covers around 60+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Cholangiocarcinoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Learn more about the emerging Cholangiocarcinoma Pipeline Therapies @ Cholangiocarcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cholangiocarcinoma Pipeline Report
* Coverage- Global
* Cholangiocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cholangiocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Cholangiocarcinoma Companies- Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
* Cholangiocarcinoma Pipeline Therapies- Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.
Dive deep into rich insights for new drugs for Cholangiocarcinoma Treatment, Visit @ Cholangiocarcinoma Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cholangiocarcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cholangiocarcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pembrolizumab: Merck Sharp & dohme
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* E7090: Eisai
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* KIN-3248: Kinnate Biopharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Cholangiocarcinoma Key Companies
* Cholangiocarcinoma Key Products
* Cholangiocarcinoma- Unmet Needs
* Cholangiocarcinoma- Market Drivers and Barriers
* Cholangiocarcinoma- Future Perspectives and Conclusion
* Cholangiocarcinoma Analyst Views
* Cholangiocarcinoma Key Companies
* Appendix
For further information on the Cholangiocarcinoma Pipeline therapeutics, reach out to Cholangiocarcinoma Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cholangiocarcinoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cholangiocarcinoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here
News-ID: 3496494 • Views: …
More Releases from ABNewswire
Schneider Electric outperforms 2023 sustainability targets and maintains its lea …
Schneider Electric, the leader in the digital transformation of energy management and automation, announced today its 2023 sustainability impact performance as part of its full-year financial results. The Schneider Sustainability Impact score for the year exceeded expectations, reaching 6.13 out of 10, and surpassing the year-end target of 6 out of 10. Schneider Electric was also recognized as a top performer by independent environmental, social, and governance (ESG) ratings throughout…
Sustainability Business Division of Schneider Electric Responds to Cybersecurity …
- Incident limited to Sustainability Business division
- No impact on any other Schneider Electric entity
- Access to business platforms reopened on January 31, 2024
- Certain data from Sustainability Business was obtained by threat actor
Note: the following statement was published on January 29, 2024, and updated on Feb. 1st and Feb. 19th, 2024. Latest update was issued to inform that certain data from Sustainability Business was obtained by the threat actor.
On…
Schneider Group-owned Lauritz Knudsen to invest Rs 850 crore in 3 years
L&T Switchgear, the electrical and automation arm of L&T, which Schneider Electric acquired in 2020, is rebranded as Lauritz Knudsen
Lauritz Knudsen, owned by Schneider Electric Group, aims to strategically invest approximately Rs 850 crore over the next three years to establish itself as a significant player in India's rapid growth trajectory in the electrical sector.
In 2020, Schneider Electric acquired L&T Switchgear, Larsen & Toubro's electrical and automation business, for Rs…
Schneider Electric launches EcoStruxure Trademark Plant Lean Management boosting …
- New, ready-to-use solution speeds up industrial digitalization.
- Plant data empowers shop floor workers and improves site performance.
- Hardware agnostic software runs on AVEVA Trademark Data Hub platform.
Schneider Electric, the leader in the digital transformation of energy management and automation, today launched EcoStruxure Plant Lean Management, a digital solution that collects and aggregates data across industrial operations to develop key performance indicators (KPIs) for short interval management (SIM) meetings, where…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Therapeutics Market New Era Of Industry and Forecast 2018-202 …
Global Cholangiocarcinoma Therapeutics Market: Overview
Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known.
Get Exclusive PDF Sample Copy Of This…
Cholangiocarcinoma Therapeutics Market Dynamic Demand by 2028
Global Cholangiocarcinoma Therapeutics Market: Overview
Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors…
Cholangiocarcinoma Therapeutics Market Global Industry Trend Analysis and Foreca …
Global Cholangiocarcinoma Therapeutics Market: Overview
Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors…
Cholangiocarcinoma Therapeutics Market - Potential Opportunities & Key players 2 …
Global Cholangiocarcinoma Therapeutics Market: Overview
Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known.
Order Brochure for more detailed…
Cholangiocarcinoma (Bile Duct Cancer) Treatment Market worth US$ 144.2 Million
In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to…
Yeliva receives FDA orphan drug status for cholangiocarcinoma
US Food and Drug Administration has granted orphan drug designation to Yeliva a first-in-class, orally administered, sphingosine kinase-2 selective inhibitor with anticancer and anti-inflammatory activities, for the effective treatment of cholangiocarcinoma. The drug is developed by RedHill Biopharma. The investigation suggested that the drug is well endured and can be safely administered to patients suffering from the disease. The action of mechanism for Yeliva includes circulation in the patient’s body…
